These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
187 related items for PubMed ID: 21150280
1. Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma. Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J, Yang J, Chen L, Zhao X, Wei Y. Cancer Biol Ther; 2011 Feb 15; 11(4):401-9. PubMed ID: 21150280 [Abstract] [Full Text] [Related]
3. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX. Cancer Biother Radiopharm; 2011 Aug 15; 26(4):427-36. PubMed ID: 21797676 [Abstract] [Full Text] [Related]
7. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Zhao XY, Nie CL, Liang SF, Yuan Z, Deng HX, Wei YQ. Biomed Pharmacother; 2012 Dec 15; 66(8):597-602. PubMed ID: 23153503 [Abstract] [Full Text] [Related]
8. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC. Wang H, Tao Z, Feng M, Li X, Deng Z, Zhao G, Yin H, Pan T, Chen G, Feng Z, Li Y, Zhou Y. Biochem Biophys Res Commun; 2020 Dec 10; 533(3):368-375. PubMed ID: 32962858 [Abstract] [Full Text] [Related]
9. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway. Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H. Theranostics; 2021 Dec 10; 11(5):2108-2122. PubMed ID: 33500714 [Abstract] [Full Text] [Related]
10. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, Yu C. Oncol Rep; 2016 Jul 10; 36(1):49-56. PubMed ID: 27220401 [Abstract] [Full Text] [Related]
12. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X. Oncol Rep; 2015 Mar 10; 33(3):1235-42. PubMed ID: 25592872 [Abstract] [Full Text] [Related]
13. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. Chan KK, Wong OG, Wong ES, Chan KK, Ip PP, Tse KY, Cheung AN. Int J Cancer; 2018 Sep 15; 143(6):1456-1469. PubMed ID: 29663364 [Abstract] [Full Text] [Related]
14. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL. Anticancer Agents Med Chem; 2019 Sep 15; 19(6):740-749. PubMed ID: 30836927 [Abstract] [Full Text] [Related]
18. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma. Ma H, Nie C, Chen Y, Li J, Xie Y, Tang Z, Gao Y, Ai S, Mao Y, Sun Q, Lu R. Oncol Res; 2021 Sep 07; 28(7):745-761. PubMed ID: 33573708 [Abstract] [Full Text] [Related]
19. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Feng B, Wang R, Chen LB. Cancer Lett; 2012 Apr 28; 317(2):184-91. PubMed ID: 22120675 [Abstract] [Full Text] [Related]